EYPT - Eyepoint Pharmaceuticals Inc logo

Eyepoint Pharmaceuticals Inc

EYPT

EyePoint Pharmaceuticals develops therapeutics for serious retinal diseases using its bioerodible Durasert E technology for sustained drug delivery. Its lead candidate, DURAVYU, targets eye conditions like wet AMD and diabetic macular edema in clinical trials.

โš•๏ธ Healthcare NASDAQ Listed 2005 $ USD
$1,000 invested 20 years ago โ†’$4today

Score Overview

1 Year
Score
Net Growth-47.66%
Net TrendShrank
Net Income Consistencyโ€”
Rev Growth-91.78%
Rev TrendShrank
Revenue Consistencyโ€”
5 Years
Score1.7
Net Growth-486.34%
Net Trend20%
Net Income Consistencyโ€”
Rev Growth-93.02%
Rev Trend40%
Revenue Consistencyโ€”
10 Years
Score
Net Growth-13x
Net Trend30%
Net Income Consistency
Rev Growth59.20%
Rev Trend60%
Revenue Consistency
20 Years
Score2.2
Net Growth-303.71%
Net Trend40%
Net Income Consistency
Rev Growth44.48%
Rev Trend55%
Revenue Consistency
All Time
Score
Net Growth-5x
Net Trend38%
Net Income Consistency
Rev Growth148.94%
Rev Trend57%
Revenue Consistency

Explore the 2021 public Archive ranking โ†’

Where Eyepoint Pharmaceuticals Inc has ranked, year by year

Measure
Fundamentals Window

Showing 10 years ranking history by HDB Score.

Has not reached the top 50 on HDB Score in any year we have ranked.

  • EYPT

2016: 63.1% ยท 2021: 97.7% ยท free through 2021 ยท longest runs

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-11-17
$ 0.30โ€”
1 Year2025-11-17
$ 13.13-97.75%
5 Years2021-11-17
$ 18.40-98.39%
10 Years2016-11-17
$ 19.10-98.45%
20 Years2006-11-17
$ 77.60-99.62%
All Time2005-01-27
$ 401.60-99.93%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 2M-$ 342M$ 118M
2025$ 31M-$ 231M$ 306M
2024$ 43M-$ 130M$ 370M
2023$ 46M-$ 70M$ 331M
2022$ 41M-$ 102M$ 144M
2021$ 36M-$ 58M$ 211M
2020$ 34M-$ 45M$ 44M
2019$ 20M-$ 56M$ 22M
2018$ 5M-$ 53M$ 38M
2017$ 7M-$ 18M$ 16M
2016$ 1M-$ 21M$ 16M
2015$ 26M$ 6M$ 28M
2014$ 26M$ 6M$ 28M
2013$ 3M-$ 13M$ 18M
2012$ 2M-$ 11M$ 10M
2011$ 3M-$ 24M$ 14M
2010$ 4M-$ 8M$ 24M
2009$ 23M$ 8M$ 17M
2008$ 12M-$ 2M$ 9M
2007$ 3M-$ 75M$ 15M
2006$ 1M-$ 84M$ 4M
IPO2005$ 1M-$ 46M$ 9M
EYPT - Eyepoint Pharmaceuticals Inc logo

Eyepoint Pharmaceuticals Inc fundamental performance

Between 2015 and 2025, revenue grew from $ 26M to $ 31M and net income went from $ 6M to -$ 231M. Revenue increased in 6 of those 10 years; net income in 3.

Across Eyepoint Pharmaceuticals Inc's full reported history, from 2005 to 2025, revenue grew from $ 1M to $ 31M and net income went from -$ 46M to -$ 231M. Revenue increased in 57% of the years measured; net income in 38%.

Eyepoint Pharmaceuticals Inc currently holds a 20-year HDB Score of 2.2 out of 10. How the HDB Score is calculated.

Membership

Continue EYPTโ€™s history

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 5,187 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$149 / year

or $19/month

Continue with Membership

30-day money-back guarantee.

Explore other companies